Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 699 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Euglycemic diabetic ketoacidosis
Leonid Barski,Tamar Eshkoli,Evgenia Brandstaetter,Alan Jotkowitz
European Journal of Internal Medicine.2019;63()9
[DOI]
2Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence
Niki Katsiki,George Dimitriadis,George Hahalis,Nikolaos Papanas,Nikolaos Tentolouris,Filippos Triposkiadis,Vasilios Tsimihodimos,Costas Tsioufis,Dimitri P. Mikhailidis,Christos Mantzoros
Metabolism.2019;96()92
[DOI]
3Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
Heidi Storgaard,Jonatan I. Bagger,Filip K. Knop,Tina Vilsbøll,Jørgen Rungby
Basic & Clinical Pharmacology & Toxicology.2016;118(2)168
[DOI]
4Sodium–glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
Shinji Tanaka,Yuki Sugiura,Hisako Saito,Mai Sugahara,Yoshiki Higashijima,Junna Yamaguchi,Reiko Inagi,Makoto Suematsu,Masaomi Nangaku,Tetsuhiro Tanaka
Kidney International.2018;94(5)912
[DOI]
5Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
AwadheshKumar Singh,Ritu Singh
Indian Journal of Endocrinology and Metabolism.2016;20(1)32
[DOI]
6Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
AwadheshKumar Singh
Indian Journal of Endocrinology and Metabolism.2015;19(6)722
[DOI]
7Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Niki Katsiki,Richard Ofori-Asenso,Ele Ferrannini,Mohsen Mazidi
Diabetes, Obesity and Metabolism.2020;22(6)1001
[DOI]
8Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy
D Dutta,S Kalra,M Sharma
Journal of Postgraduate Medicine.2017;63(2)114
[DOI]
9Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement
Sanjay Kalra,Sujoy Ghosh,AH Aamir,Md. Tofail Ahmed,MohammodFeroz Amin,Sarita Bajaj,ManashP Baruah,Uditha Bulugahapitiya,AK Das,Mimi Giri,Sonali Gunatilake,SaeedA Mahar,Md. Faruque Pathan,NazmulKabir Qureshi,SAbbas Raza,Rakesh Sahay,Santosh Shakya,Dina Shreshta,Noel Somasundaram,Manilka Sumanatilleke,AG Unnikrishnan,AchiniMadushani Wijesinghe
Indian Journal of Endocrinology and Metabolism.2017;21(1)210
[DOI]
10Diabetic Ketoacidosis in A Patient with Type 2 Diabetes On Canagliflozin and Dexamethasone
Lisa D. Alexander,Catherine Yu
AACE Clinical Case Reports.2017;3(4)331
[DOI]
11Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
T. S. Panevin,M. S. Eliseev,M. V. Shestakova,E. L. Nasonov
Terapevticheskii arkhiv.2020;92(5)110
[DOI]
12Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus
Hala Ahmadieh,Sami Azar
Diabetes Technology & Therapeutics.2017;19(9)507
[DOI]
13Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
Sanjay Kalra,Jubbin Jacob,ManashP Baruah
Indian Journal of Endocrinology and Metabolism.2018;22(1)164
[DOI]
14Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
Vishal Gupta,William Canovatchel,BN Lokesh,Ravi Santani,Nishant Garodia
Indian Journal of Endocrinology and Metabolism.2017;21(6)909
[DOI]
15Dapagliflozin for the treatment of type 1 diabetes mellitus
Kalliopi Pafili,Efstratios Maltezos,Nikolaos Papanas
Expert Opinion on Investigational Drugs.2017;26(7)873
[DOI]
16Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
Sanjay Kalra,Arpit Jain,Jignesh Ved,AG Unnikrishnan
Indian Journal of Endocrinology and Metabolism.2016;20(5)725
[DOI]
17Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
Hongyu Qiu,Aleksandra Novikov,Volker Vallon
Diabetes/Metabolism Research and Reviews.2017;33(5)e2886
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal